1. Home
  2. CXDO vs ALXO Comparison

CXDO vs ALXO Comparison

Compare CXDO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CXDO

Crexendo Inc.

HOLD

Current Price

$6.10

Market Cap

196.9M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.24

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CXDO
ALXO
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.9M
172.8M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
CXDO
ALXO
Price
$6.10
$1.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
★ $10.92
$4.60
AVG Volume (30 Days)
172.0K
★ 1.5M
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 166.67
26.36
EPS
★ 0.05
N/A
Revenue
★ $68,167,000.00
N/A
Revenue This Year
$42.60
N/A
Revenue Next Year
$13.69
N/A
P/E Ratio
$123.60
★ N/A
Revenue Growth
★ 12.05
N/A
52 Week Low
$5.35
$0.86
52 Week High
$11.23
$2.66

Technical Indicators

Market Signals
Indicator
CXDO
ALXO
Relative Strength Index (RSI) 58.62 47.40
Support Level $5.96 $0.86
Resistance Level $6.71 $1.30
Average True Range (ATR) 0.25 0.15
MACD 0.06 0.04
Stochastic Oscillator 88.49 74.93

Price Performance

Historical Comparison
CXDO
ALXO

About CXDO Crexendo Inc.

Crexendo Inc is a software technology company that provides cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services. The company operates through two segments: Cloud Telecommunications Services and Software Solutions. Its cloud telecommunications segment generates revenue from the provision of broadband Internet services, managed IT services, software license sales, and infrastructure as a service. The software solutions segment derives revenues from three primary sources: software licenses, software maintenance support and professional services. The majority of the company's revenue is derived from the Cloud Telecommunications Services segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: